Lee Kachiu C, Peacock Sue, Weinstock Martin A, Zhao Ge Alice, Knezevich Stevan R, Elder David E, Barnhill Raymond L, Piepkorn Michael W, Reisch Lisa M, Carney Patricia A, Onega Tracy, Lott Jason P, Elmore Joann G
Department of Dermatology, Brown University, Providence, Rhode Island.
Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
J Am Acad Dermatol. 2017 Jan;76(1):121-128. doi: 10.1016/j.jaad.2016.07.029. Epub 2016 Sep 28.
The extent of variability in treatment suggestions for melanocytic lesions made by pathologists is unknown.
We investigated how often pathologists rendered suggestions, reasons for providing suggestions, and concordance with national guidelines.
We conducted a cross-sectional survey of pathologists. Data included physician characteristics, experience, and treatment recommendation practices.
Of 301 pathologists, 207 (69%) from 10 states (California, Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, Utah, and Washington) enrolled. In all, 15% and 7% reported never and always including suggestions, respectively. Reasons for offering suggestions included improved care (79%), clarification (68%), and legal liability (39%). Reasons for not offering suggestions included referring physician preference (48%), lack of clinical information (44%), and expertise (29%). Training and caseload were associated with offering suggestions (P < .05). Physician suggestions were most consistent for mild/moderate dysplastic nevi and melanoma. For melanoma in situ, 18 (9%) and 32 (15%) pathologists made suggestions that undertreated or overtreated lesions based on National Comprehensive Cancer Network (NCCN) guidelines, respectively. For invasive melanoma, 14 (7%) pathologists made treatment suggestions that undertreated lesions based on NCCN guidelines.
Treatment suggestions were self-reported.
Pathologists made recommendations ranging in consistency. These findings may inform efforts to reduce treatment variability and optimize patterns of care delivery for patients.
病理学家对黑素细胞性病变提出的治疗建议的变异性程度尚不清楚。
我们调查了病理学家提出建议的频率、提供建议的原因以及与国家指南的一致性。
我们对病理学家进行了一项横断面调查。数据包括医生特征、经验和治疗推荐实践。
在301名病理学家中,来自10个州(加利福尼亚州、康涅狄格州、夏威夷州、爱荷华州、肯塔基州、路易斯安那州、新泽西州、新墨西哥州、犹他州和华盛顿州)的207名(69%)参与了研究。总体而言,分别有15%和7%的人报告从不和总是包括建议。提供建议的原因包括改善护理(79%)、澄清(68%)和法律责任(39%)。不提供建议的原因包括转诊医生的偏好(48%)、缺乏临床信息(44%)和专业知识(29%)。培训和工作量与提供建议有关(P < 0.05)。医生的建议在轻度/中度发育异常痣和黑色素瘤方面最为一致。对于原位黑色素瘤,分别有18名(9%)和32名(15%)病理学家根据美国国立综合癌症网络(NCCN)指南提出了对病变治疗不足或过度治疗的建议。对于侵袭性黑色素瘤,14名(7%)病理学家根据NCCN指南提出了对病变治疗不足的治疗建议。
治疗建议是自我报告的。
病理学家提出的建议一致性程度不一。这些发现可能为减少治疗变异性和优化患者护理模式的努力提供参考。